A new study from Pfizer, focusing on how adolescent teenagers respond to the COVID-19 vaccine, showed promising results.

The company, one of three to have gotten an emergency use authorization for a coronavirus vaccine for people aged 18 or older, said on Wednesday that a new trial focused on teenagers aged 12-15 years old demonstrated 100% efficacy.